Patients with heterozygous familial hypercholesterolemia (FH) and coronary heart disease have high mortality rates. However, in an era of high-dose statin prescription after acute coronary syndrome (ACS), the risk of recurrent coronary and cardiovascular events associated with FH might be mitigated. We compared coronary event rates between patients with and without FH after ACS.
ORIGINAL RESEARCH ARTICLE 699 h eterozygous familial hypercholesterolemia (FH) is a common monogenic disorder associated with elevated low-density lipoprotein (LDL) cholesterol levels and premature coronary heart disease (CHD). Several definitions of FH have been proposed by expert groups that use LDL cholesterol and/or personal or family history of premature CHD. [1] [2] [3] Unfortunately, FH remains largely underdiagnosed in the general population, and many patients with FH are diagnosed only at the time of their first coronary event. 4 In Europe, up to 8% of adults hospitalized for acute coronary syndromes (ACS) have been shown to have clinical criteria compatible with FH, 5, 6 which is >10 times greater than the prevalence of FH in the general population. However, even if FH is frequent among patients with premature CHD, there is still no established screening strategy to decrease the number of missed diagnoses. 7 Moreover, prognosis data are lacking in patients with FH in the setting of ACS, particularly in the era of widespread statin use.
The benefit of statins versus placebo on cardiovascular outcomes for patients with FH has never been established in a randomized, controlled trial. 8, 9 Furthermore, very few data document the likelihood of cardiovascular event recurrence in patients with ACS with FH compared with those with no FH. 10 Thus, it is unknown whether further identification of FH is required for a more targeted secondary prevention approach, despite the widespread adoption of high-dose statins after ACS. Accordingly, we investigated whether a diagnosis of FH among ACS patients was associated with a greater recurrence risk of coronary events compared with ACS patients without FH independently of cardiovascular risk factors and severity of ACS.
MethODs study Population
The SPUM-ACS study (Special Program University Medicine-Acute Coronary Syndromes) is a prospective cohort study of consecutive patients hospitalized with ACS in Switzerland. The study was designed to identify new determinants and consequences of CHD. Details of the methods of the SPUM-ACS study have been reported previously. [11] [12] [13] Briefly, all patients hospitalized with ACS in 4 university hospitals in Switzerland were invited to participate with no exclusion criteria except severe physical disability, inability to give consent owing to dementia, and life expectancy of <1 year for noncardiac reasons. Inclusion criteria were age ≥18 years, a main diagnosis of ST-elevation-elevation myocardial infarction for patients presenting after pain onset, non-ST-segment-elevation myocardial infarction, or unstable angina. Overall, clinical followup information at 1 year was available for 5045 of patients included in the SPUM-ACS cohort study between September 2009 and September 2013. Baseline lipid measurements were missing for 453 patients (9%), and an additional 58 patients (1.3%) had missing family history information. Thus, the final population for this analysis included 4534 patients.
Diagnosis of Fh
The diagnosis of FH was based on 3 different definitions recommended by international guidelines (Tables I-III in the onlineonly Data Supplement) . The latest statement of the American Heart Association combined LDL cholesterol >190 mg/dL and a family history of a first-degree relative with premature CHD. 1 The Simon Broome definition recommended by National Institute for Health and Care Excellence guidelines used total cholesterol >290 mg/dL or LDL cholesterol >190 mg/dL and a personal or family history of premature coronary disease. 3 Finally, the Dutch Lipid Clinic definition also used LDL cholesterol levels and a personal or family history of premature CHD. A possible FH was defined by a score of 3 to 5, and a probable/definite FH by a score of ≥6. 2 As done previously, 5 cutaneous signs and genetic tests of FH were counted as zero in all definitions because this type of information was missing for too many patients. For the Simon Broome definition in which such items are included, only a possible diagnosis of FH could be provided.
clinical Outcomes
The occurrence of clinical events during the first year after hospitalization for ACS was obtained by monitoring participants by telephone at 30 days after discharge and again in a clinical face-to-face visit at 1 year after ACS. Coronary events were defined as the occurrence of fatal or nonfatal myocardial infarction. Cardiovascular events were defined as the occurrence of myocardial infarction, ischemic stroke, transient ischemic clinical Perspective What is new?
• With the use of clinical criteria proposed by several expert groups, the prevalence of familial hypercholesterolemia (FH) reached 5% in a large cohort of patients hospitalized with acute coronary syndrome (ACS) in Switzerland, which may be 10 times greater than in the general population. • Although nearly all patients with FH were discharged on statins, mostly high-dose statins, only a few achieved the recommended low-density lipoprotein cholesterol levels 1 year after ACS. • Patients with FH had a 2-fold increased risk of coronary event recurrence within the first year after ACS compared with same-age patients without FH.
What are the clinical implications?
• These results demonstrate the necessity to measure low-density lipoprotein cholesterol and to encourage systematic screening for FH at the time of ACS. • A better identification of patients with FH after ACS is required to individualize the intensity of lipidlowering treatment and to better tailor secondary prevention because novel lipid-lowering drugs such as proprotein convertase subtilisin kexin 9 inhibitors are anticipated to further reduce the risk of coronary event recurrence in ACS patients with FH. attack, or cerebrovascular or cardiovascular mortality. All cardiovascular end points used in this analysis were adjudicated by a panel of 3 certified cardiologists who served as independent experts blinded to the diagnosis of FH.
covariables Total cholesterol, high-density lipoprotein cholesterol, and triglycerides levels were measured in the first blood draw at the emergency department within 24 hours of admission and immediately processed locally with standardized and certified dose methods. LDL cholesterol was calculated with the Friedewald formula when triglyceride levels were <394 mg/dL. LDL cholesterol was considered missing for patients with triglyceride levels of ≥394 mg/dL (1.9% missing). Lipid-lowering drugs that were taken before hospitalization and prescribed at discharge were systematically collected by trained study nurses. For patients using lipid-lowering drugs before hospitalization for ACS, we estimated untreated LDL cholesterol levels on the basis of the type and dose of lipid-lowering medication used before hospitalization, applying a correcting factor for LDL cholesterol adapted to the reported efficacy of each drug, as done previously for similar analyses. 6, 14 Pre-existing cardiovascular disease was defined as a previous diagnosis of CHD, ischemic cerebrovascular disease, or peripheral artery disease. Personal history of premature CHD was considered positive when men were <55 years old and women were <60 years old at the time of first ACS. 5 Family history of premature CHD was based on patient reports of a coronary event in a brother or father <55 years old or a mother or sister <60 years old. Education status was dichotomized as having graduated from high school or university or having a lower-level education. Hypertension was defined as a systolic blood pressure ≥140 mm Hg or diastolic blood pressure ≥90 mm Hg or use of blood pressure-lowering drugs. Blood pressure-lowering drugs included all medications in the classes of angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, β-blockers, calcium channel blockers, diuretics, and nitrates. Smoking status was categorized into current, former, and never smokers. Former smokers were those who smoked at least 1 cigarette a day during at least 1 year and were nonsmokers for >1 month before inclusion. Diabetes mellitus was either self-reported or diagnosed by the use of antihyperglycemic medication or a hemoglobin A 1c of ≥6.5% at admission.
statistical analysis
At the time of hospitalization for ACS, we categorized patients according to the presence of FH for each definition and reported clinical characteristics in each group, as well as in patients not selected by any definition of FH. We assessed the associations between FH diagnosis and cardiovascular and coronary outcomes using unadjusted and multivariable Cox proportional hazard models. In the first model, we adjusted only for age and sex. In the second model, we adjusted for traditional cardiovascular risk factors, including age, sex, body mass index, current smoking, hypertension, and diabetes mellitus. In the third model, we further adjusted for high-intensity statins at discharge and attendance at cardiac rehabilitation. In the final model, we further adjusted for results of the 6-month prognosis GRACE (Global Registry of Acute Coronary Events) score to account for the severity of ACS. The GRACE risk score used to calculate long-term mortality or the composite of all-cause mortality or recurrent MI included age, heart rate, systolic blood pressure, initial serum creatinine, history of congestive heart failure, history of myocardial infarction, elevated cardiac markers (conventional troponins as per local laboratories), ST-segment depression, and in-hospital revascularization. 11, 15 In an exploratory analysis, we further adjusted our final model to baseline LDL cholesterol levels to examine the role of LDL cholesterol in the risk of events among patients with FH. We applied a log transformation for LDL cholesterol because of right-skewed distribution.
For the coronary and cardiovascular events analysis, first events occurring within 1 year after the index hospitalization were considered (myocardial infarction, ischemic stroke, transient ischemic attack, cerebrovascular or cardiovascular mortality, all-cause death), and time to event was censored at 365 days after the index hospitalization.
To account for age differences between patients with FH and those without FH, we additionally assessed the prognosis of FH in young patients with premature CHD only and computed unadjusted Kaplan-Meier curves. Further sensitivity analyses were performed by including only patients who were not using lipid-lowering drugs at the time of hospitalization for ACS to account for the potential overestimation of FH prevalence with this method. All hypothesis tests were 2 sided, and the significance level was set at 5%. Statistical analyses were performed with STATA 14 (STATA Corp, College Station, TX).
ethics statement
The Medical Ethics Committee of each center (Lausanne, Geneva, Bern, and Zurich) approved the study, and all participants gave written informed consent to participate in the study.
resUlts
Among 4534 patients hospitalized with ACS, 2.5% were identified with FH with the American Heart Association definition and 5.5% with the Simon Broome definition, whereas 18.2% were identified with possible FH and a further 1.6% with probable/definite FH with the Dutch Lipid Clinic definition. Overall, 79.2% of patients with ACS had no criteria for FH. Clinical characteristics of patients with and without FH are reported in Table 1 . Compared with patients without FH, patients with FH were <10 years younger and presented more often with a first cardiovascular event and an ST-elevation-elevation myocardial infarction. Patients with FH identified with the American Heart Association definition were older, were more frequently women, and presented more frequently with hypertension than patients with FH identified with other definitions.
During the year after hospitalization for ACS, 153 patients (3.4%) died, 217 (4.8%) had a fatal or nonfatal myocardial infarction, and 275 (6.1%) experienced a cardiovascular event. Unadjusted rates of coronary and cardiovascular events were similar between patients with and without FH, but patients with FH were 10 years Table 3 for patients with and without FH. Among patients identified with FH according to at least 1 definition, 98.6% were discharged with any statins, and 77.3% were discharged with high-dose statins. One year after ACS, high-dose statins were still used by >70% of patients with FH, but <10% scored the 70-mg/dL LDL cholesterol target. Among patients without FH, 67% were discharged with high-dose statins, and 56% were still on high-dose statins 1 year after ACS, with nearly 38% reaching the 70-mg/dL LDL cholesterol target.
Stratified analyses performed in 1369 patients with premature CHD showed an increased risk of coronary events for patients with FH compared with patients without FH in both the unadjusted and multivariableadjusted models ( Table 4 and Figure 2 ). For cardiovascular events, statistical significance was reached for the Simon Broome definition only. Restricting the analysis to 3234 patients not using lipid-lowering drugs at baseline yielded roughly similar risk estimates but with larger confidence intervals ( Table IV in 
DiscUssiOn
In this multicenter, observational study, the prevalence of FH was 1.6% to 5.5% (depending on which clinical definition of FH was used) among patients hospitalized Data are given as mean (SD) when appropriate. ACC indicates American College of Cardiology; ACS, acute coronary syndrome; AHA, American Heart Association; eGFR, estimated glomerular filtration rate; FH, familial hypercholesterolemia; GRACE, Global Registry of Acute Coronary Events; HDL, highdensity lipoprotein; LDL, low-density lipoprotein; NSTEMI, non-ST-segment-elevation myocardial infarction; PCI, percutaneous coronary intervention; STEMI, ST-segment-elevation myocardial infarction; and TIMI, Thrombolysis in Myocardial Infarction.
*Defined as a high school or university graduation or higher. †Defined as >14 units of alcohol a week. ‡Defined as a systolic blood pressure ≥140 mm Hg or diastolic blood pressure ≥90 mm Hg or use of blood pressure-lowering drugs. §Based on patient self-report, use of antihyperglycemic medication/insulin, or hemoglobin A 1c ≥6.5%. ‖Defined as coronary heart disease, ischemic cerebrovascular disease, or peripheral artery disease.
¶Age of onset for ACS <55 years in men and <60 years in women. #Self-reported history of a major cardiovascular event in a brother or father <55 years old or a mother or sister <60 years old. **Include statins, fibrates, ezetimibe, niacin, and resins. † †Include angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, β-blockers, calcium channel blockers, or diuretics. ‡ ‡Include age, heart rate, systolic blood pressure, initial serum creatinine, history of congestive heart failure, history of myocardial infarction, elevated cardiac markers (conventional troponins as per local laboratories), ST-segment depression, and in-hospital revascularization.
§ §Lowest TIMI flow per patient. for ACS, which demonstrates that the prevalence of FH may be 3 to 10 times greater than in the general population. 16, 17 We further reported that patients with FH identified with clinical criteria had a >2-fold increase in risk of recurrent coronary events within 1 year after discharge compared with patients without FH after multivariable ad-justment and despite more frequent use of high-intensity statins. This association between FH clinical diagnosis and recurrent coronary events was independent of cardiovascular risk factors and severity of ACS. Previous studies assessed the cardiovascular risk of patients with FH compared with population-based cohorts from the general population, but none prospectively compared the recurrence of cardiovascular events after CHD in patients with or without FH, nor did they adjust the prognosis of FH according to cardiovascular risk factors and severity of CHD. The Simon Broome Register Group reported mortality rates of patients with FH. [18] [19] [20] These studies were conducted mainly in primary prevention, and ≈70% of men and 80% of women had no pre-existing CHD at the beginning of follow-up. However, the benefit of statins may differ between primary and secondary prevention among patients with FH. 20 Furthermore, recommendations for clinical management of patients with FH and CHD should also be based on the recurrence of nonfatal clinical events. One study carried out in Dutch lipid clinics prospectively examined the rates of coronary events in patients with FH without a record of pre-existing cardiovascular disease. 9 Other studies in Dutch lipid clinics were retrospective or cross-sectional, and cardiovascular risk estimates may have been prone to confounding biases. 14, 21 One prospective study in a single lipid clinic in the Netherlands examined the risk of recurrence of cardiovascular events in 131 patients with FH and pre-existing CHD who were treated with statins. 10 However, they did not adjust recurrence estimates to cardiovascular risk factors, statin dose, or severity of CHD. To the best of our knowledge, our study is the first to prospectively assess the risk of coronary and cardiovascular event rates in a large cohort of patients with FH after ACS who were treated with high-intensity statins. Despite wide implementation of high-dose statins after ACS, patients with FH remain at increased risk of recurrence compared with patients without FH after accounting for age. In clinical practice, the implementation of a systematic screening strategy for FH is limited by the costs of genetic testing and counseling. 22 Because cardiovascular risk was shown to be driven by both phenotype and genotype, 21,23 expert groups proposed simplified definitions for establishing a diagnosis of FH based on clinical criteria. [1] [2] [3] In our study, we were able to demonstrate how these simplified screening algorithms using cholesterol levels and family or personal history of premature CHD as diagnostic criteria were powerful and efficient tools to identify FH in patients with ACS at high risk of coronary event recurrence despite high-intensity statin treatments. Furthermore, treatments other than lipid-lowering drugs such as dual antiplatelet therapy were prescribed more often in patients with FH than in those without FH. Patients with FH also had better coronary flow after percutaneous coronary intervention than patients without FH. Overall, these factors may have led to underestimation of the risk ratios we reported.
We also reported that additional adjustment with baseline LDL cholesterol at the time of ACS did not further reduce the risk gap between patients with and without FH. From these results, we propose that the elevated cardiovascular risk in ACS patient with FH may be explained by lifelong persistence of elevated LDL cholesterol levels, as well as familial susceptibility to atherosclerosis.
Novel lipid-lowering drugs such as proprotein convertase subtilisin kexin 9 inhibitors are anticipated to further reduce the risk of cardiovascular disease in patients with heterozygous FH, in whom low levels of LDL cholesterol cannot be achieved with statins only. 24, 25 However, in light of the high cost of proprotein convertase subtilisin kexin 9 inhibitors, prescription strategies for these drugs will need to target specifically those adults most likely benefit from intensified lipid management such as patients with FH. 26 The benefit of systematically identifying patients with FH at the time of hospitalization for ACS to reduce the recurrence of cardiovascular events still needs to be demonstrated. Nevertheless, FH is a frequent disorder among patients with ACS, with prevalence rates reaching 15% in some studies. 5, 6, 27, 28 Systematic screening for FH based on clinical criteria has been shown to be easy to carry out and affordable. With the added benefits that proprotein convertase subtilisin kexin 9 inhibitors are expected to bring in terms of cardiovascular events reduction, systematic screening for FH should be encouraged in patients with ACS until further evidence is available.
Our study has strengths and limitations. Our results have strong external validity because our study population was derived from nonselected patients with ACS in 4 different centers, in contrast to previous studies that were conducted mainly in lipid clinics. 10, 14, 18, 19 However, the increased recurrence risk of coronary events applies only to patients with ACS with FH. Despite the fact that we adjusted our estimate to the severity of ACS, selection bias of patients with FH who have some unmeasured confounder leading them to be hospitalized at varying rates than patients without FH also is possible. 29 We were not able to assess the concordance of the rates of FH measured according to the clinical definitions we chose for its diagnosis with the results of genetic testing for FH. Because clinical criteria without molecular diagnosis may overestimate the prevalence of FH, many of our patients classified as having FH may in fact have polygenic hypercholesterolemia. 23, 30 This misclassification could, in turn, have underestimated the cardiovascular risk of patients classified as FH, as suggested by the greater risk ratio associated with FH compared with polygenic hypercholesterolemia in the probable/definite category of the Dutch Lipid Clinic definition. In other words, patients with a confirmed genetic diagnosis of FH may be at even greater risk of cardiovascular events than what we found in our study. Furthermore, we did not collect data on family history of high LDL cholesterol levels or on skin manifestations such as xanthoma. Overall, these missing data decreased the sensitivity of the Simon Broome and the Dutch Lipid Clinic definitions. On the other hand, we found a consistent association between FH and cardiovascular events across all 3 clinical definitions for FH. 31 Also of note is that LDL cholesterol levels are lowered 12 to 24 hours after an ACS, another cause that could have led to the prevalence of FH being underestimated in our study. 32, 33 This potential misclassification of FH may, in turn, have decreased the relative incremental risk associated with FH. Finally, we used self-reported information on family history of premature CHD, and a recall bias may have occurred in patients with ACS, leading to an overestimation of FH prevalence. However, recent data presented by others showed similar reporting accuracy of family history in patients with and without pre-existing cardiovascular disease. 34 cOnclUsiOns Patients with FH hospitalized for ACS are at high risk of coronary event recurrence after discharge despite the AHA indicates American Heart Association; CI, confidence interval; FH, familial hypercholesterolemia; and HR, hazard ratio. *Adjusted for age, sex and cardiovascular risk factors, including body mass index, current smoking, hypertension, diabetes mellitus, pre-existing cardiovascular disease, high-intensity statins at discharge, attendance to cardiac rehabilitation at discharge, and results of the 6-months GRACE (Global Registry of Acute Coronary Events) risk score.
use of high-dose statins. In the era of systematic prescription of high-dose statins, measuring cholesterol levels at the time of ACS diagnosis has been considered superfluous. On the other hand, our results suggest that patients with FH need to be identified because they are less likely to reach target LDL cholesterol levels. Proper identification of patients with FH will also be useful for testing new approaches in individualized treatment such as novel lipidlowering drugs, family counseling, and tailored secondary prevention. Finally, the intensification of lipid management and secondary prevention in patients with FH may reduce the recurrence of cardiovascular events.
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